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The prototypic arenavirus lymphocytic choriomenin-
gitis virus (LCMV), which naturally persists in
rodents, represents a model for HIV, HBV, and
HCV. Cleavage of the viral glycoprotein precursor
by membrane-bound transcription factor peptidase,
site 1 (Mbtps1 or site-1 protease), is crucial for the life
cycle of arenaviruses and therefore represents
a potential target for therapy. Recently, we reported
a viable hypomorphic allele of Mbtps1 (woodrat)
encoding a protease with diminished enzymatic
activity. Using the woodrat allele, we examine the
role of Mbtps1 during persistent LCMV infection.
Surprisingly, Mbtps1 inhibition limits persistent but
not acute viral infection and is associated with an
organ/cell type-specific decrease in viral titers. Anal-
ysis of bone marrow-derived dendritic cells from
woodratmice supports their specific role in resolving
persistent viral infection. These results support
in vivo targeting of Mbtps1 in the treatment of arena-
virus infections and demonstrate a critical role for
dendritic cells in persistent viral infections.
INTRODUCTION
Membrane-bound transcription factor peptidase, site 1
(Mbtps1), also known as site-1 protease (S1P), cleaves several
host and viral proteins. Host cell substrates include S1P itself,
b-ZIP transcription factors such as the sterol regulatory element
binding proteins (SREBP1 and SREBP2), ATF6, CREBH, CREB4,
OASIS, and Luman (Chen et al., 2002; Nadanaka et al., 2004;
Ye et al., 2000). Cleavage of the SREBP transcription factors
permits nuclear translocation and expression of genes required
for the synthesis and uptake of cholesterol (Brown et al., 2000).
Cleavage of ATF6 mediates one aspect of the unfolded protein
response (UPR), by inducing expression of Grp78(BiP) and
Grp94 which encode key chaperones required for the UPR212 Cell Host & Microbe 9, 212–222, March 17, 2011 ª2011 Elsevier(Ron and Walter, 2007). Viral glycoproteins are also a target of
S1P. Cleavage of the glycoprotein precursor (GPC) is a crucial
step in the life cycle of all major human pathogenic arenaviruses,
including lymphocytic choriomeningitis virus (LCMV) and Lassa
hemorrhagic fever virus, as well as for the bunyavirus Crimean-
Congo hemorrhagic fever virus (Bergeron et al., 2007; Rojek
et al., 2010). In the course of evolution, these viruses have seized
upon the catalytic activity of S1P and its location in the endo-
plasmic reticulum and Golgi apparatus to process their envelope
glycoproteins. Processing of the GPC by S1P is necessary for
cell-to-cell propagation of infection and production of infectious
virus in S1P-deficient cells in vitro (Rojek et al., 2010). The conse-
quences of complete deficiency of S1P in vivo cannot be
assessed, because the knockout allele is embryonic lethal in
homozygous form (Yang et al., 2001). Recently, we reported
a viable hypomorphic allele of Mbtps1 (woodrat; wrt) encoding
a S1P protein with diminished enzymatic activity. Wrt homozy-
gotes are less likely to survive to birth and are prone to dextran
sulfate sodium-induced colitis by virtue of their defective UPR
(Brandl et al., 2009). The wrt/– genotype is lethal in utero, sug-
gesting that the hypomorphic effect of the mutation is relatively
severe.
Here, we have tested the effects of the wrt mutation on resis-
tance to the prototypic Arenavirus family member, lymphocytic
choromeningitis virus (LCMV). We find that persistent viral infec-
tion is impossible in the context of restricted S1P activity and
infer a critical role for bone marrow-derived dendritic cells
(bmDCs) in the maintenance of persistence.
RESULTS
woodrat Mice Are Resistant to Persistent
LCMV Clone13 Infection
S1P is required for arenavirus life cycle in vitro (Rojek and Kunz,
2008). Therefore, we hypothesized that C57BL/6Jmice homozy-
gous for the hypomorphic Mbtps1wrt allele (Brandl et al., 2009)
would be resistant to arenaviral challenge. However, our original
studies with the acute strain of the prototypic arenavirus,
lymphocytic choriomeningitis virus Armstrong strain (LCMV
Arm), showed no striking defects in viral growth kinetics in vitro
or in vivo (Figures 1A, 2A, and 4A). Given the critical role ofInc.
10
5
10
6 WT Cl13
Wrt Cl13
Wrt ARM
WT ARM
A
0 20 40 60
10
2
10
3
10
4
3
WT ARM
WT Cl13
8
10 WT ARM
WT Cl13
Wrt ARM +
CB
1
2 Wrt ARM
Wrt Cl13
2
4
6
Wrt Cl13
%
 
T
e
t
r
a
m
e
r
2.5 2.5
0 0
ED
1.0
1.5
2.0
GP33 NP396
1.0
1.5
2.0
γ
a
n
d
 
T
N
F
α
+
0.0
0.5
0.0
0.5
WT 
ARM
Wrt
ARM
WT 
Cl13
Wrt
Cl13
Wrt
ARM
Wrt
Cl13
%
 
I
F
N
WT 
ARM
WT 
Cl13
Figure 1. Mbtps1wrt (wrt) Are Resistant to LCMV Cl13 Infection Despite Immunodeficiency
(A) Mbtps1wrt are resistant to persistent LCMV Cl13 infection, but the kinetics of viremia are not altered during infection with the acute LCMV Armstrong (ARM)
parent strain. Mean and SEM are shown from 6–12 mice/group at the indicated times after infection.
(B and C) GP33 ex vivo peptide stimulation (B) and viral peptide-specific T cell enumeration (C) with tetramers from splenocytes 5 dpi.
(D and E)Mbtps1wrt mount a CTL immune response to LCMV Cl13, 9 dpi, when WT CTL exhibit exhaustion. GP33 (D) and NP396 (E) ex vivo peptide stimulation
from splenocytes. Mean and SEM are shown from six mice/group. *p < 0.05, **p < 0.005.
See also Figure S1.
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woodrat Mutation Protects against Persistent VirusMbtps1 in arenavirus growth and our knowledge that proteolytic
activity was functionally compromised in some tissues (Brandl
et al., 2009), we hypothesized that a persistent variant of
LCMV Arm, LCMV Clone 13 (Cl13), that infects a distinct set of
target cells compared with LCMV Arm would exhibit altered
in vivo growth. Only two amino acids distinguish the acute
LCMV Arm virus from persistent LCMV Cl13 virus. Our lab and
others have shown that these differing residues do not lie within
immunodominant epitopes that engage the critical cytotoxic
CD8+ T cell response required for viral clearance. Instead, these
two residues affect viral tropism that is thought to be the primary
variable resulting in viral persistence versus acute viral clearance
(Sevilla et al., 2000; Sevilla et al., 2004a). Although LCMV Arm is
completely cleared by the host immune responsewithin 2weeks,
LCMV Cl13 maintains high levels of viremia for 2–3 months fol-
lowed by extended or even life-long viral persistence in the
kidney (de la Torre and Oldstone, 1996; Oldstone, 2002; RecherCell Hoet al., 2007). Interestingly, we could not detect LCMV Cl13 in
tissues examined at 3 weeks after infection in Mbtps1wrt, as
observed in infections by the acute LCMV Arm strain (Figure 2A).
woodratMice Clear a Normally Persistent Virus Despite
Being Immunodeficient
LCMV persistence relies on replication during an ongoing host
immune response. We hypothesized that wrt host resistance
was largely due to defective viral replication in bmDCs and
perhaps other cell types secondary to defective GP processing.
However, host resistance might also be due to an augmented
antiviral immune response. Therefore, we directly measured the
dominant effectors in LCMV clearance (Jamieson et al., 1987;
Li et al., 2009; van der Most et al., 1996) focusing on the T and
B lymphocyte responses. We measured both the numbers and
function of viral antigen specific lymphocyte responses in wrt
versus WT controls (Table 1 and Figures 1B and 1C).st & Microbe 9, 212–222, March 17, 2011 ª2011 Elsevier Inc. 213
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Figure 2. Mbtps1wrt Are Susceptible to Establishment of LCMV Cl13 Infection in Serum, Spleen, Liver, and Kidney, but Have an Early
Sustained Defect in the Bone Marrow
(A)Mbtps1wrt are susceptible to LCMVCl13 replication in serum, spleen, liver, and kidney. Mean and SEM are shown from four to six mice/group at the indicated
times after infection.
(B) In the bone marrow, monocytes and DCs have defective establishment of LCMV Cl13 in Mbtps1wrt. Mean and SEM are shown from five mice/group, 5 dpi.
*p < 0.05, **p < 0.005.
See also Figure S2.
Cell Host & Microbe
woodrat Mutation Protects against Persistent VirusBy enumerating viral antigen-specific T cells andmeasuring their
effector function as indicated by cytokine production and direct
ex vivokilling byCD8cells, aswell as specificantibody responses
in vivo, we found that wrt immune responses were diminished
compared to WT controls in the first week of infection (Table 1
and Figures 1B and 1C). However, as wrt do clear the normally
persistent LCMV Cl13, we reasoned that their residual immune
response must be sufficient to eliminate infected cells. Consis-
tent with this hypothesis, we observed an augmented immune
response in wrt T cells 9 days postinfection (dpi) in comparison
to the otherwise ‘‘exhausted’’ response normally found in persis-
tently LCMV Cl13 infected WT animals (Figures 1D and 1E).
woodrat Resistance Is Not Reversed with Cholesterol
Supplementation
To find alternative explanations for the protective effect of thewrt
mutation, we supplemented mice with a 5% cholesterol diet214 Cell Host & Microbe 9, 212–222, March 17, 2011 ª2011 Elsevier(sufficient to partially restore wrt T cell immune deficiency; Table
1) and challenged them with LCMV Cl13. Given the important
requirement of cholesterol in both the viral life cycle and host
immune responses (Bukrinsky and Sviridov, 2006; Riethmu¨ller
et al., 2006; Rojek et al., 2008), we hypothesized that limiting
amounts of cholesterol were responsible for wrt resistance.
However, cholesterol repletion did not revert wrt resistance
(Figure S1A available online). As another possibility, we
assessed whether type I interferon production might partially
explain wrt resistance. However the increase in IFNalpha that
we observed did not meet statistical significance (Figure S1B),
and its mechanistic contribution is unclear at this time.
Defective LCMV Cl13 Establishment in Bone
Marrow and Kidney
As tropism is thought to be one of the key factors distinguishing
viral clearance versus persistence, we examined the kinetics ofInc.
Table 1. Mbtps1wrt Are Immunodeficient when Challenged with LCMV Armstrong
Diet Parameter Mbtps1WT/WT Mbtps1Wrt/WT Mbtps1Wrt/Wrt Mbtps1Wrt/Wrt + 5% Cholesterol Diet
Primary Response
Regular 7 dpi %IFNg+np396+CD8+ 6 ± 1 7 ± 3 0.4a ± 3 n.d.
Regular 7 dpi %IFNg+gp33+CD8+ 2 ± 1 2 ± 0.6 0.4a ± 0.2 n.d.
Cholesterol 7 dpi specific cytotoxic activity n.d. 57 8a 39
Cholesterol 28 dpi anti-LCMV antibodies n.d. 860 263a 643
Secondary Response
Regular 74 dpi %IFNg+np396+CD8+ 5 ± 1 12 ± 3 7 ± 0.2 n.d.
Regular 74 dpi %IFNg+gp33+CD8+ 4 ± 0.8 5 ± 0.4 4 ± 1 n.d.
Diet and dpi are indicated for ex vivo peptide stimulation assay, cytotoxic killing assay, and anti-LCMV antibody titers. *p < 0.05.
aMbtps1Wrt/Wrt yielded statistically significant results as compared to the corresponding controls.
Cell Host & Microbe
woodrat Mutation Protects against Persistent Virusviral replication in several organs (Figure 2A). Surprisingly, we
found normal establishment of viral infection in spleen and liver
5 dpi. However, acutely high viral loads in bone marrow and
kidney were not observed after LCMV Cl13 infection of
Mbtps1wrt homozygotes (Figure 2A) at this time point. Resis-
tance is observed in both tissues despite the presence of high
levels of infectious virus in the blood. However, at 9 dpi, similar
levels of LCMV Cl13 were found in the kidneys of WT and wrt
mice. However, no appreciable amount of infectious virus or viral
antigen was detected in the bone marrow of Mbtps1wrt at any
time (Figures 2A and 2B).
Recent work has implicated bone marrow in establishing
persistent viral infection (Carter et al., 2010) and, more specifi-
cally, DCs and their progenitors are thought to be critical for
persistent viral infections including LCMV Cl13 (Sevilla et al.,
2003; Sevilla et al., 2004a). Thus, we further analyzed viral repli-
cation in the bone marrow of Mbtps1wrt homozygotes. We
analyzed bone marrow cells utilizing flow cytometry and found
that both Mbtps1wrt/wrt DCs and their monocyte precursors
were resistant to LCMVCl13 infection (Figure 2B). This is specific
to the bone marrow environment as Mbtps1wrt/wrt splenic DCs
are readily infected at this time (Figure 3). Consistent with
a bone marrow-specific defect in Mbtps1wrt/wrt mice, we also
observed a loss of the usual conversion of granulocyte dominant
to monocyte dominant bone marrow cells during LCMV Cl13
infection of Mbtps1wrt/wrt mice (Figure S2).
LCMVCl13 Establishes Infection inMbtps1wrt/wrt Spleen
Because splenic DC infection has been implicated as a critical
factor for LCMV Cl13 persistence (Sevilla et al., 2004a), we
hypothesized that with limiting amounts of S1P there would be
decreased virus production in splenic DCs. However, instead
we observed an increase in the number of DCs expressing the
LCMV nucleoprotein (NP) in Mbtps1wrt/wrt (Figures 3A and 3B).
Although viral protein was abundant in Mbtps1wrt/wrt DCs, we
further sought to determine whether fully processed infectious
virus might still be diminished. However, we observed that
Mbtps1wrt/wrt DCs indeed produced equivalent, if not more, cells
containing infectious progeny than their WT counterparts (Fig-
ure 3). In contrast to reduced viral loads in the bone marrow
compartment, neither Mbtps1wrt/wrt B or T lymphocytes nor
DCs or bulk unsorted splenocytes showed diminished numbers
of infectious centers. Therefore, the LCMV growth defect in
Mbtps1wrt/wrt bone marrow is specific.Cell HoMbtps1 Expression and Downstream Gene Expression
Is Decreased in woodrat Bone Marrow
Given the surprising finding that splenocytes supported produc-
tive viral replication, in striking contrast to cells from the bone
marrow, we assessed the levels of Mbtps1 expression, as well
as the genes it regulates in spleen, kidney, liver, and bone
marrow. We hypothesized that Mbtps1 expression might be
limited in the bone marrow. Therefore, further downregulation
of Mbtps1 in wrt would be insufficient for the critical amount of
protease activity needed for a productive viral infection. Indeed,
we observed a lower level of basal Mbtps1 expression in the
bone marrow as compared to other organs tested (Figure S3).
This is consistent with a decreased level of Mbtps1 expression
in bone marrow as compared with almost all other organs as
cataloged in both human and mice by BioGPS (Wu et al., 2009).
AsMbtps1 encodesaproteasewhosemain function is to activate
gene transcription programs, we also assessed for the levels of
these target genes in spleen, kidney, liver, and bone marrow.
Consistent with decreased expression of Mbtps1 in wrt bone
marrow, we observed a decrease in Mbtps1 regulated genes
most dramatically in the bone marrow of wrt as compared to
WT mice (Figure S3B). Interestingly, we observed an increase in
expression ofMbtps1 inducible genes in the spleen ofwrt versus
the WT (Figure S3B). This could contribute to the robust produc-
tive viral infection we observed in wrt splenocytes (Figure 2).
Defective LCMV Replication in bmDCs but not Bone
Marrow Macrophages or Primary Fibroblasts
AsMbtps1wrt/wrt monocytes and DCs exhibit specific resistance
to LCMV Cl13 infection, we cultured bone marrow from
Mbtps1wrt/wrt animals to investigate viral replication in two
related professional antigen-presenting cells (APCs), macro-
phages, and DCs that were infected selectively by LCMV Cl13
(Matloubian et al., 1993; Sevilla et al., 2000, 2004a).We observed
that viral growth kinetics in Mbtps1wrt/wrt bone marrow-derived
macrophages (bmMOs) and primary fibroblasts were essentially
indistinguishable from the WT in single and multistep growth
curves (Figures 4A and 4C). Consistent with unchanged viral
growth kinetics, we observed efficient processing of LCMV
GPC (Figure 4B). Occasionally, we have seen decreased total
amounts of LCMV GPC in Mbtps1wrt/wrt primary fibroblasts.
However, we have never observed a defect in the processing
of this protein. In contrast, LCMV replication was almost
completely abrogated in Mbtps1wrt/wrt bmDCs (Figure 4C).st & Microbe 9, 212–222, March 17, 2011 ª2011 Elsevier Inc. 215
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Figure 3. Mbtps1wrt Splenic DCs Are Susceptible to LCMV Cl13 Infection
(A) Splenocytes were stained for the intracellular viral antigen NP conjugated to qDot655 and alexa488. Gated DCs shown were CD11c+,NK1.1–,CD3–. Flow
cytometry dataset is summarized in (B).
(B) Mean and SEM from six mice are shown.
(C) Splenocytes were sorted for B, T, and dendritic cells. Cells bearing infectious virus were quantitated by infectious center assay. All mice were analyzed 9 dpi.
Mean and SEM from six mice are shown. *p < 0.05, **p < 0.005.
See also Figure S3.
Cell Host & Microbe
woodrat Mutation Protects against Persistent Viruswoodrat Resistance Is Restricted by the S1P
Cleavage Site
Wehypothesized that diminished LCMV growth in bmDCswould
map to ineffective S1P cleavage at position 270 after the amino
acid recognition site RRLA. Therefore, we utilized a previously
characterized virus whereby the RRLA recognition sequence
was replaced with the Furin recognition site RRRR (Rojek
et al., 2010), referred to as ‘‘LCMV-Furin.’’ In contrast to WT
virus, which requires S1P cleavage of viral GPC to complete its
viral life cycle and is insensitive to Furin proteases, LCMV-Furin
does not require S1P but instead requires Furin to complete its
life cycle (Rojek et al., 2010). We observed that LCMV-Furin
grows with kinetics similar to LCMV-WT in WT bmDCs, indi-
cating that Furin is sufficient to replace the function of WT S1P,
as indicated by prior studies (Rojek et al., 2010). Importantly,
LCMV-Furin proliferated in Mbtps1wrt/wrt bmDCs to an extent
similar to its proliferation inMbtps1WT/WT cells and the prolifera-
tion of WT virus in Mbtps1WT/WT cells (Figure 4D). Next, we
directly assessed the cleavage of GPC biochemically in wrt
and WT bmDCs. Consistent with our genetic experiment
whereby the RRRR Furin recognition site was able to rescue viral
growth in wrt bmDCs (Figure 4D), we observed no processing of
viral GPC to its cleavage products GP1 and GP2 in wrt bmDCs
(Figure 4E). Even with overexposure and/or overloading of
protein, we were not able to detect any processing of GPC (Fig-
ure 4E, bottom panels).216 Cell Host & Microbe 9, 212–222, March 17, 2011 ª2011 ElsevierIn order to rule out other explanations for diminished viral
production in Mbtps1wrt/wrt bmDCs, we determined whether
there was increased death of Mbtps1wrt/wrt bmDCs compared
toWT bmDCs. We did not see a significant effect of the mutation
on cell death (Figures S4A–S4C). In addition, we examined
whether viral protein production might be diminished in wrt
bmDCs to account for the decrease in infectious progeny.
However, we did not observe any diminution in LCMV proteins
in Mbtps1wrt/wrt bmDCs utilizing monoclonal antibodies against
the nucleoprotein and glycoprotein or polysera against all
LCMVantigens (FigureS4Danddatanot shown). Taken together,
these data show failure of cleavage at the viral RRLA S1P recog-
nition sequence within bmDCs as the mechanism for the genetic
protection afforded by the hypomorphicMbtps1wrt allele.
Next, we challengedwrt andWTmice with recombinant LCMV
Cl13 viruses bearing either the native S1P or Furin recognition
sequences. In contrast to our ex vivo experiments, the mutant
Furin site altering amino acids 268 and 269 resulted in decreased
viral fitness in vivo. However, consistent with our ex vivo findings,
Cl13FURIN produced significantly higher viral titers than the parent
wild-type virus (Cl13S1P) in wrt mice. Importantly, despite the
attenuating effect of the Furin mutation inWTmice, this mutation
demonstrated an increased fitness that was specific towrtmice.
We observed that Cl13S1P was rapidly cleared in wrt versus WT
mice (similar to the passaged isolate), whereas Cl13FURIN had
equivalent (or better) replicative fitness in wrt versus WT miceInc.
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Figure 4. Mbtps1wrt Fibroblasts and Macrophages Support Viral Growth in Contrast to Dendritic Cells in which Viral Growth Is Restricted by
the S1P Cleavage Site, RRLA
(A) Ex vivo multistep LCMV Cl13 growth curves in wrt versus WT primary fibroblasts. Mean and SEM are shown for one of two similar independent experiments
(n = 4).
(B) Western blot of LCMV GP from wrt and WT primary fibroblasts. GPC, GPC nonglycosylated (NG), and processed GP2 are visualized with the monoclonal
antibody 83.6. Concentrated LCMV stock was used as a positive control. n = 3.
(C) Ex vivo LCMV Cl13 growth curves in wrt versus WT primary bone marrow-derived macrophages and dendritic cells (bmMO and bmDC, respectively). Cells
were inoculated at a multiplicity of infection (MOI) of 0.1 and 0.001 as shown. Mean and SEM of viral titers are shown for one of two similar independent exper-
iments (n = 4).
(D) Ex vivo LCMV growth curves in wrt versus WT bmDCs with recombinant virus containing the native LCMV Mbtps1 cleavage site (RRLA), designated S1P,
versus the Furin protease cleavage site (RRRR) in lieu of RRLA, designated FURIN. MOI = 0.1. Similar results were seen using either the Armstrong or Cl13 viral
backbones. Mean and SEM of viral titers are shown for one of two similar independent experiments (n = 4).
(E) Western blot of LCMV GP from wrt and WT bmDCs. Lysates were collected 24 hours postinfection and blotted for GPC and its cleavage products, GP1 and
GP2. One of three experiments is shown.
(F) Recombinant viruses containing either the native S1P cleavage site, RRLA, or the Furin recognition site, RRRR, were used to infectwrt andWTmice.Micewere
bled on the indicated days after infection and titered for infectious virus. Mean and SEM of viral titers are shown for one of two similar independent experiments
(n = 4). Of note, Cl13FURIN serum levels were significantly higher at 5 dpi in wrt mice as compared to the parent virus, Cl13S1P in wrt. *p < 0.05; **p < 0.005.
See also Figure S4.
Cell Host & Microbe
woodrat Mutation Protects against Persistent Virus(consistent with our ex vivo bmDC findings). Furthermore, we
sequenced virus fromwrt animals to test whether the Furinmuta-
tion might not be tolerated in vivo. However, for both Cl13FURIN
and Cl13S1P the GPC protease site was identical between the
input and output viruses (data not shown), consistent with the
selective advantage of the RRRR recognition site in wrtmice.Cell HoAdoptive Transfer of woodrat bmDCs Prevents
Persistent Viral Infection
Given our data regarding the potential contribution of bmDCs,
we adoptively transferred wrt bmDCs to assess their ability to
protect otherwise susceptible WT hosts. Consistent with our
prior findings that implicated a role for DCs in persistent viralst & Microbe 9, 212–222, March 17, 2011 ª2011 Elsevier Inc. 217
Figure 5. Adoptive Immunotherapy with Mbtps1wrt bmDCs
(A) bmDCs were cultured from WT and wrt mice. Eight million bmDCs were adoptively transferred intravenously into 8- to 10-week-old recipient WT B6 mice.
Either 1 hr after or 2 days prior to infection with 2 3 106 PFU LCMV Cl13, bmDCs were adoptively transfered to recipient B6 mice. Serum was harvested and
titered at the indicated times. Mean and SEM from eight mice/group are shown.
Cell Host & Microbe
woodrat Mutation Protects against Persistent Virus
218 Cell Host & Microbe 9, 212–222, March 17, 2011 ª2011 Elsevier Inc.
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woodrat Mutation Protects against Persistent Virusinfection (Figures 2B, 4C, and 4D) (Sevilla et al., 2000, 2003,
2004a), we observed that wrt bmDCs alone were capable of
conferring resistance to persistent viral infection (Figure 5A).
Although the establishment of acute viremia was indistinguish-
able whether recipients received WT DCs or wrt bmDCs versus
vehicle, persistent viremia could only be quelled with wrt
bmDC immunotherapy. However, this effect was not seen
when wrt bmDCs were delivered after 2 days of infection
(Figure S5A).
Previously, we have shown that Cl13 subverts DC function by
inhibiting MHC and costimulatory molecules (Sevilla et al.,
2004b). We hypothesized that wrt bmDCs might be resistant to
this viral subversion given the observed resistance to productive
viral infection (Figure 4C). This would result in an augmented
adaptive immune response and therefore could provide an
explanation for the kinetics of viral clearance seen with wrt
bmDC immunotherapy. Flow cytometric analysis of bmDCs in-
fected ex vivo confirmed our prior findings that Cl13 infected
DCs do not upregulate antigen presentation and costimulatory
molecules as expected (Figure 5B). Surprisingly,wrt bmDCs dis-
played augmented basal activation of MHC and costimulatory
molecules. This activation was not significantly inhibited by
Cl13 infection. However, this did not translate into increased
T cell cytokine responses 7 dpi (Figure S5B). Thus,wrtDCsmight
be acting as a sink for viral replication more so than contributing
to a greater inflammatory response.
DISCUSSION
These studies focused on the therapeutic target S1P by
utilizing the hypomorphic mutant woodrat to evaluate systemic
S1P inhibition in vivo. As Mbtps1wrt is the only viable animal
model with systemic inhibition of S1P, this reagent provides
a powerful means to assess the role of S1P inhibition in vivo.
Therapeutically, Mbtps1 is an important potential target in the
treatment of hypercholesterolemia and often fatal arenavirus
infections. We directly assessed the role for this gene for
both the acute and persistent variants of the prototypic arena-
virus LCMV.
Surprisingly, in vivo resistance in this model was observed
mainly in chronic infection (Clone 13 infection), without a promi-
nent role in acute infection (Armstrong infection). As expected,
this hypomorphic mutation in a gene required for the viral life
cycle does result in a decrease in viral titers. However, this
decrease is organ and cell type specific. Our interpretation of
these data is that persistent viral infection requires infection
and viral subversion of specific cell types that are genetically
resistant to infection in Mbtps1wrt (i.e., bone marrow cells,
including monocytes and DCs), implicating an important role
for these cell types in persistent versus acute infections. We
believe these cells might be more sensitive to the wrt mutation
(in contrast to splenocytes or hepatocytes) due to a lower level
of S1P activity in cells from the bone marrow. Indeed, we
observed lower expression of both Mbtps1 as well as down-(B)wrt bmDCs have higher levels of MHCmolecules (class I and class II) and costi
WT and wrtmice are shown with mean and SEM for both the percent of cells in hi
one of two similar independent experiments (n = 4). *p < 0.05.
See also Figure S5.
Cell Hostream target genes in bone marrow as compared to other
compartments. Given the hypomorphic activity of Mbtps1 in
wrt, this would further decreaseMbtps1 function below a poten-
tially critical threshold necessary for a productive viral infection in
the bone marrow.
In order to confirm the mechanism of protection in wrt, we
applied a genetic test, host complementation. In this test, muta-
tion of the viral proteolytic recognition sequence for Mbtps1,
RRLA to RRRR, which can be recognized by the ubiquitous
protease Furin, should restore viral fitness in the wrt host. This
restoration of viral replication should be specific to mutations
in both the host and viral genes involved. Consistent with this
reasoning, we observed specific rescue of Cl13FURIN viral repli-
cation in wrt bmDCs. Moreover, complementation was also
observed in vivo. Cl13FURIN had increased viral fitness in wrt as
compared to otherwise more susceptible WT mice. Of note, it
remains unclear why Cl13FURIN is ultimately attenuated in vivo.
We have observed many times prior that various engineered
viruses that we have produced display severe in vivo attenuation
that was not seen in vitro (D.L.P., B.M.S., and J.C.d.l.T., unpub-
lished data) (Emonet et al., 2009). We suspect that the numerous
differences in cell type and extracellular milieu in vivo versus
in vitro contribute to this phenomenon. Importantly, our observa-
tions were specific to the proteolytic cleavage site in the LCMV
GPC and the cognatemutation in the proteaseMbtps1.Although
the two amino acid changes in Cl13FURIN attenuate the virus
in vivo in an unknown manner, the selective advantage offered
by complementing viral proteolytic cleavage with Furin
outweighs the cost of utilizing the mutant RRRR site. We
confirmed this by directly sequencing viral GPC 5 dpi from
serum. In all cases, we observed no deviation from the engi-
neered protease target sequences in output virus as compared
to the sequence in the inoculating virus. Importantly, mainte-
nance of the RRRR recognition site in wrt serum is despite
normal processing in several cell types as well as equivalent
productive infection in organs (i.e., spleen and liver) at this time
inwrt as compared to WT mice. Importantly, these findings offer
insight toward the importance of cell type specificity when tar-
geting viral processing activity. This is imminently important for
HIV/AIDS research regarding protease inhibitors in clinical use.
These studies highlight the importance of studying genes
systemically in vivo utilizing a hypomorphic mutation when null
mutations are nonviable. In this way, one can compare the rela-
tive roles of different cell types in a physiologically relevant situ-
ation where a therapeutic target is partially inhibited. When
limited to complete nulls many therapeutic targets can no longer
be studied secondary to embryonic lethality. In addition,
complete target inhibition is physiologically unlikely in real-world
settings.
Utilizing wrt mice in this study, we have uncovered two key
findings regarding therapeutic targeting of S1P: inhibition of
S1P function results is host lymphocyte immunodeficiency,
and inhibition of S1P is a therapeutically viable option for
treatment of persistent arenavirus infection in vivo. Thesemulatory molecules (CD80 and CD86). Flow cytometric analysis of bmDCs from
ghly activated gate as well as gMFI for MHC and costimulatory molecules from
st & Microbe 9, 212–222, March 17, 2011 ª2011 Elsevier Inc. 219
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inhibition for treatment of hypercholesterolemia and often-fatal
arenavirus infections (Hawkins et al., 2008; Hay et al., 2007).
Understanding the consequences of systemic inhibition of this
therapeutic target is critical in determining its clinical utility.
Regarding our understanding of persistent viral infection,
analysis of the wrt mutation has demonstrated two critical
findings—the role of cell type specificity in controlling persistent
viral infection, and the potential therapeutic utility of bmDCs in
protection from persistent viral infection.
We have found cell type-specific resistance to viral growth
in bmDCs. In response to this finding and to growing literature
supporting the central role of DCs in persistent viral infections
and tumor immune escape (Chaput et al., 2008; Liu et al.,
2009; Oldstone, 2009; Zwirner et al., 2010), we tested the
therapeutic role of bmDCs that are genetically resistant to
LCMV challenge. We believe that wrt bmDCs are therapeutic in
contrast to WT bmDCs for two reasons. First, DCs express
a high level of the arenavirus receptor alpha-dystroglycan
(B.M.S. and M.B.O., unpublished data), but after viral entry this
becomes a dead end for viral replication in wrt bmDCs, effec-
tively a sink for infectious virus particles. Second, we observed
basal activation in wrt bmDCs that is not inhibited by Cl13 infec-
tion. Being a critical cell type in persistent viral infections, this
may also contribute to host protection, although as we did not
observe augmentation in virus specific peptide stimulation 7
dpi, this appears to play a smaller role, if any.
Our results raise an important consideration when transferring
DCs therapeutically into patients. There has been much specu-
lation and experimentation in further supplementing a host with
DCs to combat both infectious and oncologic diseases (Ilett
et al., 2010; Lehman et al., 2010). Our data highlight that simply
boosting the levels of these central immune sentinels may not be
sufficient to clear a pathogenic challenge. This is likely
secondary to the numerous subversive tactics already in place
compromising the host immune response. Rather, optimizing
this cell type to resist infectious or oncologic countermeasures,
as in our model, may be critical to fully utilize DCs and other
immune cell types to advance the field of immunotherapy.EXPERIMENTAL PROCEDURES
Mice and Viruses
C57BL/6J mice were from the Rodent Breeding Colony at The Scripps
Research Institute. C57BL/6J mice were used for ENU mutagenesis to
generate the woodrat strain, as described at http://mutagenetix.scripps.edu/.
Allmicewere housedunder specific pathogen-free conditions.Mousehandling
conformed to the requirements of the National Institutes of Health and The
Scripps Research Institute Animal Research Committee. Mice were infected
intravenously with 2 3 106 plaque-forming units (PFU) LCMV-Arm or LCMV-
Cl 13. For testing of immunologic memory and protection, mice were rechal-
lenged intravenously with 2 3 106 PFU of LCMV-Cl 13. Viral stocks were
prepared and viral titers were measured as previously described (Evans
et al., 1994).
Cell Isolation
Total splenic DCs (CD45+CD3–NK1.1–CD19–CD11c+), B cells (CD45+CD3–
NK1.1–CD11c–CD19+), and T cells (CD45+CD3+NK1.1–CD11c–CD19–) were
sorted with a FACSVantage fluorescence activated cell sorter (Becton Dickin-
son) as previously described (Zuniga et al., 2004). Purities for all populations
after sorting were >99%.220 Cell Host & Microbe 9, 212–222, March 17, 2011 ª2011 ElsevierIntracellular Cytokine Analysis and Flow Cytometry
Splenocytes were stimulated for 5 hr with 5 mg/ml of the MHC class II-
restricted LCMV GP61–80 or 2 mg/ml of the MHC class I-restricted
LCMV NP396–404 or GP33–41 (all >99% pure; Peprotech) in the presence
of 50 U/ml recombinant murine IL-2 (Peprotech) and 1 mg/ml brefeldin
A (BD PharMingen). Addition of IL-2 to the ex vivo stimulation did not alter
cytokine production (data not shown). Cells were stained for surface expres-
sion of CD4 (clone RM4-5, PharMingen) and CD8 (clone 53-6.7, Caltag). Cells
were fixed, permeabilized, and stained with antibodies to TNF-a (clone MP6-
XT22), IFN-g (clone XMG1.2), and IL-2 (clone JES6-5H4). Flow cytometric
analysis was performed with a Digital LSR II (Becton Dickinson). MHC class
I and class II tetramers were produced and used for staining as previously
described (Homann et al., 2001).Immunofluorescent Microscopy
Three-color imageswere collectedwith anAxiovert S100 immunofluorescence
microscope (Zeiss) fitted with an automated xy stage and an Axiocam color
digital camera. So that these tissues could be obtained, organs were removed
and frozen in OCT and 6 mm frozen sections were cut and stained overnight
at 4C with a guinea pig polysera to LCMV (1:2,000 dilution), NP113 mouse
monoclonal specific for LCMV NP, 83.6 mouse monoclonal specific for
LCMV GP, and/or ER-TR7 rat monoclonal (Abcam) (all at 1 mg/ml final concen-
tration). Tissuesor 96-well plate bound cellswerewashed and incubated at 4C
for 3 hr with species specific secondary antibodies, washed, and incubated
with 4,6-diamidino-2-phenylindole (DAPI, 1 mg/ml) prior to imaging.51Cr Release Assays
In vitro 51Cr release assays were performed on day 9 after infection. MC57
target cells were labeled with 1mg/ml LCMVGP33–41 or NP396–404 peptides
or left unlabeled, and then mixed with splenocytes at a 50:1 effector/target
ratio. Samples were performed in triplicate and 51Cr release was measured
in the supernatant after 5 hr as previously described (Borrow et al., 1995).DNA Transfection and Rescue of LCMV from Cloned
Complementary DNAs
Virus rescue was done as described previously (Flatz et al., 2006). Subconflu-
ent BHK-21 cells (23 106 cells perM6well) were transfected for 5 hr with 2.5 ml
Lipofectamine 2000 (Invitrogen) per microgram of plasmid DNA. The RRLA site
naturally found in LCMV Clone 13 GPC sequence was changed to the Furin
recognition site, RRRR, by site-directed mutagenesis.RNA Preparation and Sequencing
RNA was extracted from serum 5 dpi with TRI reagent (Molecular Research
Center). Reverse-transcription reaction was done with the Masterscript kit (5
PRIME) and primers specific for LCMV GPC. PCR amplified products were
directly sequenced.Western Blot Analysis
Cell homogenate was collected with Laemmli buffer as described previously
(Popkin et al., 2003). Protein content was determined by BCA assay (Pierce),
and protein samples were analyzed by reducing 4%–12% SDS-PAGE
(Nupage Bis-Tris-Gel; Invitrogen) and were detected with three monoclonal
antibodies, 83.6, WE-33.1, WE36.1 (all anti-LCMV GP) (Buchmeier et al.,
1981), and anti-actin or tubulin (Sigma) antibodies as loading controls.Generation of BM Chimeric Mice
Generation of BM chimeric mice was performed as described (Brandl et al.,
2009). Recipient WT (CD45.1) or Mbtps1wrt/wrt (CD45.2) mice were lethally
irradiated with 950 rad with a 137Cs source and injected intravenously 3 hr
later with 53 106 BM cells derived from the tibia and femurs of the respective
donors. Six to eight weeks after engrafting, reconstitution was assessed by
FACS analysis of bone marrow and/or peripheral blood cells. After red blood
cell lysis, cells were stained with FITC-labeled CD45.1 antibody and
PerCPCy5.5-labeled CD45.2 antibody. All animals had >99% hematopoietic
cells of donor origin.Inc.
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Bone marrow was harvested and cultured as described previously (Liou et al.,
2008; Popkin et al., 2003). GM-CSF or M-CSF (Peprotech) were kept in culture
media (both at 10ng/ml final) for bmDCs or bmMOs, respectively, during the
entire course of experiments. bmAPCs were used at 6 days after ex vivo
culture or as stated.
qRT-PCR
RNA (1.0 mg) was reverse transcribed by using random hexamers and 18-dT
and SuperScript II (Invitrogen). One one-hundredth of this product was
PCR amplified, and incorporation of SYBR green (Molecular Probes) was
quantified. All PCR reactions (primers obtained fromOriGene) were performed
in triplicate for each experiment. 18S normalized data were used to quantitate
relative levels of gene expression by using DDCt analysis.
Adoptive Transfer
bmDCswere cultured as above, and 6million cells or PBS vehicle control were
transferred on day 6 of culture into recipient C57BL/6J mice.
Statistical Analysis
Statistical analysis was performed on Prism software. All p values less than
0.05 were considered significant. Error bars denote the standard error of the
mean (SEM). * indicates p < 0.05, and ** indicates p < 0.005.
SUPPLEMENTAL INFORMATION
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